Abstract:Anti-cancer peptides (ACPs) are short peptides known for their ability to inhibit tumor cell proliferation, migration, and the formation of tumor blood vessels. In this study, we designed ACPs to target receptors often overexpressed in cancer using a systematic in silico approach. Three target receptors (CXCR1, DcR3, and OPG) were selected for their significant roles in cancer pathogenesis and tumor cell proliferation. Our peptide design strategy involved identifying interacting residues (IR) of these receptors, with their natural ligands serving as a reference for designing peptides specific to each receptor. The natural ligands of these receptors, including IL8 for CXCR1, TL1A for DcR3, and RANKL for OPG, were identified from the literature. Using the identified interacting residues (IR), we generated a peptide library through simple permutation and predicted the structure of each peptide. All peptides were analyzed using the web-based prediction server for Anticancer peptides, AntiCP. Docking simulations were then conducted to analyze the binding efficiencies of peptides with their respective target receptors, using VEGA ZZ and Chimera for interaction analysis. Our analysis identified HPKFIKELR as the interacting residues (IR) of CXCR-IL8. For DcR3, we utilized three domains from TL1A (TDSYPEP, TKEDKTF, LGLAFTK) as templates, along with two regions (SIKIPSS and PDQDATYP) from RANKL, to generate a library of peptide analogs. Subsequently, peptides for each receptor were shortlisted based on their predicted anticancer properties as determined by AntiCP and were subjected to docking analysis. After docking, peptides that exhibited the least binding energy were further analyzed for their detailed interaction with their respective receptors. Among these, peptides C9 (HPKFELY) and C7 (HPKFEWL) for CXCR1, peptides D6 (ADSYPQP) and D18 (AFSYPFP) for DcR3, and peptides P19 (PDTYPQDP) and p16 (PDQDATYP) for OPG, demonstrated the highest affinity and stronger interactions compared to the other peptides. Although in silico predictions indicated a favorable binding affinity of the designed peptides with target receptors, further experimental validation is essential to confirm their binding affinity, stability and pharmacokinetic characteristics.

Computational Design And Optimization Of Novel D-Peptide Tnf Alpha Inhibitors

De Novo Design of Helical Peptides to Inhibit Tumor Necrosis Factor-Α by Disrupting Its Trimer Formation

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

Computational Design of Helical Peptides Targeting TNFα

Design, Synthesis, and Evaluation of Dihydrobenzo[ cd ]indole-6-sulfonamide as TNF-α Inhibitors.

Design and optimisation of bioactive cyclic peptides: generation of a down-regulator of TNF secretion

Design and Synthetic Strategies for Helical Peptides.

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

Rational Design of TNFα Binding Proteins Based on the De Novo Designed Protein DS119

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Computational design of anti-cancer peptides tailored to target specific tumor markers

Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

Discovery of Novel Ligands for TNF-α and TNF Receptor-1 Through Structure-Based Virtual Screening and Biological Assay

Design of High Affinity Binders to Convex Protein Target Sites

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Computational design of cyclic peptides to inhibit protein-peptide interactions

Structure-Based Design of Peptides against G3BP with Cytotoxicity on Tumor Cells.